

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 4, 2022**

**XTANT MEDICAL HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34951**  
(Commission  
File Number)

**20-5313323**  
(IRS Employer  
Identification No.)

**664 Cruiser Lane  
Belgrade, Montana**  
(Address of principal executive offices)

**59714**  
(Zip Code)

**(406) 388-0480**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.000001 per share	XTNT	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 2.02 Results of Operations and Financial Condition.

On August 4, 2022, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company’s non-GAAP adjusted EBITDA is calculated by adding back to net loss the charges for other expense, depreciation and amortization expense, interest expense, and tax expense and further adjusted by adding back in or excluding, as appropriate, non-cash compensation, separation related expenses, and litigation reserve.

The Company uses adjusted EBITDA and the other non-GAAP measures in making operating decisions because it believes these measures provide meaningful supplemental information regarding its core operational performance. Additionally, these measures give the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses these measures to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA and other non-GAAP measures facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges.

As described above, the Company excludes the following items from its non-GAAP financial measures for the following reasons:

*Non-cash compensation.* The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.

*Separation related expenses.* The Company excludes separation related expenses from non-GAAP adjusted EBITDA primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.

---

*Litigation reserve.* The Company excludes litigation reserve from non-GAAP adjusted EBITDA primarily because such reserve is not reflective of the Company's ongoing operating results and is not used by management to assess the core profitability of the Company's business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.

Non-GAAP adjusted EBITDA is reconciled to net loss, the most directly comparable GAAP measure, in the press release.

Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company's non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company's financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company's financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.

#### **Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits.*

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release of Xtant Medical Holdings, Inc. dated August 4, 2022 entitled "Xtant Medical Announces Second Quarter Financial Results" (furnished herewith)</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**XTANT MEDICAL HOLDINGS, INC.**

By: */s/ Scott Neils*

---

Scott Neils  
*Chief Financial Officer*

Date: August 4, 2022

---



### **Xtant Medical Announces Second Quarter 2022 Financial Results**

BELGRADE, MT, August 4, 2022 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022.

“We are pleased to have achieved our highest revenue quarter since the start of the pandemic. Our second quarter revenue increased 2% over the same prior year period, including 8% year-over-year growth in our biologics business, which was fueled by strong demand for our new biologics products and expansion of our distributor network,” said Sean Browne, President and CEO of Xtant Medical. “On the strength of our four key growth pillars, our strategic initiatives are gaining traction, giving us greater confidence regarding our future prospects. Despite the impact on our business from the broader supply chain and macroeconomic challenges, our team continues to execute in bringing life changing orthobiologics and spinal implant systems to patients in need.”

#### **Second Quarter 2022 Financial Results**

Second quarter 2022 revenue was \$15.3 million, compared to \$14.9 million for the same quarter in 2021. The increase in revenue is attributed primarily to introductions of new products and increased private label and original equipment manufacturer (OEM) sales.

Gross margin for the second quarter of 2022 was 54.8%, compared to 63.5% for the same period in 2021. The decrease is primarily attributable higher product costs and increased charges for excess and obsolete inventory.

Operating expenses for the second quarter of 2022 totaled \$9.7 million compared to \$10.0 million for the second quarter of 2021. The decrease was primarily due to legal settlement expenses in 2021, partially offset by higher sales and marketing expenses in 2022.

Second quarter 2022 net loss totaled \$1.7 million, or \$0.02 per share, compared to the second quarter 2021 net loss of \$0.7 million, or \$0.01 per share.

Non-GAAP Adjusted EBITDA for the second quarter of 2022 totaled a loss of \$0.4 million, compared to Non-GAAP Adjusted EBITDA of \$0.9 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

#### **Conference Call**

Xtant Medical will host a webcast and conference call to discuss the second quarter 2022 financial results on Thursday, August 4, 2022 at 9:00 AM ET. To access the webcast, [Click Here](#). To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at [www.xtantmedical.com](http://www.xtantmedical.com) under “Investor Info.”

---

## **About Xtant Medical Holdings, Inc.**

Xtant Medical Holdings, Inc. ([www.xtantmedical.com](http://www.xtantmedical.com)) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

## **Non-GAAP Financial Measures**

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

## **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "continue," "future," "will," "potential," "going forward," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the future success of the Company's four key growth pillars and strategic initiatives and its future prospects. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; the ability to increase or maintain revenue; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory if revenues continue to decrease; the ability to remain competitive; the ability to innovate, develop and introduce new products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of the COVID-19 pandemic and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 8, 2022 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at [www.sec.gov](http://www.sec.gov), for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

## **Investor Relations Contact**

David Carey  
Lazar FINN  
Ph: 212-867-1762  
Email: [david.carey@finnpartners.com](mailto:david.carey@finnpartners.com)

---

**XTANT MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands, except number of shares and par value)

	As of June 30, 2022	As of December 31, 2021
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$ 16,495	\$ 18,243
Restricted Cash	352	144
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of \$510 and \$552, respectively	8,600	7,154
Inventories	16,461	17,945
Prepaid and other current assets	424	844
Total current assets	<u>42,332</u>	<u>44,330</u>
Property and equipment, net	5,529	5,212
Right-of-use asset, net	1,033	1,258
Goodwill	3,205	3,205
Intangible assets, net	372	400
Other assets	242	287
Total Assets	<u>\$ 52,713</u>	<u>\$ 54,692</u>
<b>LIABILITIES &amp; STOCKHOLDERS' EQUITY</b>		
Current Liabilities:		
Accounts payable	\$ 3,043	\$ 2,615
Accrued liabilities	4,538	4,349
Current portion of lease liability	479	462
Current portion of finance lease obligations	60	31
Line of credit	3,736	3,620
Total current liabilities	<u>11,856</u>	<u>11,077</u>
Long-term Liabilities:		
Lease liability, less current portion	598	842
Finance lease obligations, less current portion	213	103
Long-term debt, plus premium and less issuance costs	11,902	11,787
Total Liabilities	<u>24,569</u>	<u>23,809</u>
Stockholders' Equity		
Preferred stock, \$0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, \$0.000001 par value; 300,000,000 shares authorized; 87,313,701 shares issued and outstanding as of June 30, 2022 and 87,068,980 shares issued and outstanding as of December 31, 2021	-	-
Additional paid-in capital	267,252	266,068
Accumulated deficit	(239,108)	(235,185)
Total Stockholders' Equity	<u>28,144</u>	<u>30,883</u>
Total Liabilities & Stockholders' Equity	<u>\$ 52,713</u>	<u>\$ 54,692</u>

**XTANT MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited, in thousands, except number of shares and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2022	2021	2022	2021
<b>Revenue</b>				
Orthopedic product sales	\$ 15,277	\$ 14,942	\$ 28,227	\$ 27,451
Other revenue	-	33	9	66
Total Revenue	<u>15,277</u>	<u>14,975</u>	<u>28,236</u>	<u>27,517</u>
<b>Cost of sales</b>				
Cost of sales	6,903	5,460	12,302	9,911
Gross Profit	<u>8,374</u>	<u>9,515</u>	<u>15,934</u>	<u>17,606</u>
Gross Profit %	54.8%	63.5%	56.4%	64.0%
<b>Operating Expenses</b>				
General and administrative	3,797	4,173	7,766	7,200
Sales and marketing	5,636	5,590	10,845	10,445
Research and development	241	243	454	458
Total Operating Expenses	<u>9,674</u>	<u>10,006</u>	<u>19,065</u>	<u>18,103</u>
Loss from Operations	(1,300)	(491)	(3,131)	(497)
<b>Other Expense</b>				
Interest expense	(397)	(199)	(757)	(201)
Total Other Expense	<u>(397)</u>	<u>(199)</u>	<u>(757)</u>	<u>(201)</u>
Net Loss Before Provision for Income Taxes	<u>(1,697)</u>	<u>(690)</u>	<u>(3,888)</u>	<u>(698)</u>
Provision for Income Taxes	(13)	(43)	(35)	(64)
Net Loss	<u>\$ (1,710)</u>	<u>\$ (733)</u>	<u>\$ (3,923)</u>	<u>\$ (762)</u>
<b>Net Loss Per Share:</b>				
Basic	\$ (0.02)	\$ (0.01)	\$ (0.04)	\$ (0.01)
Dilutive	\$ (0.02)	\$ (0.01)	\$ (0.04)	\$ (0.01)
<b>Shares used in the computation:</b>				
Basic	87,313,701	86,707,286	87,252,521	83,993,159
Dilutive	87,313,701	86,707,286	87,252,521	83,993,159



**XTANT MEDICAL HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited, in thousands)

	<b>Six Months Ended</b>	
	<b>June 30,</b>	
	<b>2022</b>	<b>2021</b>
<b>Operating activities:</b>		
Net loss	\$ (3,923)	\$ (762)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	599	731
Gain on disposal of fixed assets	(84)	(108)
Non-cash interest	116	16
Non-cash rent expense	(1)	5
Stock-based compensation	1,184	921
Provision for reserve on accounts receivable	143	(143)
Provision for excess and obsolete inventory	825	211
Changes in operating assets and liabilities:		
Accounts receivable	(1,589)	38
Inventories	659	104
Prepaid and other assets	465	(29)
Accounts payable	428	(308)
Accrued liabilities	189	266
Net cash (used in) provided by operating activities	<u>(989)</u>	<u>942</u>
<b>Investing activities:</b>		
Purchases of property and equipment	(810)	(1,079)
Proceeds from sale of fixed assets	165	125
Net cash used in investing activities	<u>(645)</u>	<u>(954)</u>
<b>Financing activities:</b>		
Payments on financing leases	(22)	(34)
Costs associated with refinancing	-	(32)
Payments on long-term debt	-	(484)
Borrowings on line of credit	26,567	9,331
Repayments of line of credit	(26,451)	(9,009)
Proceeds from private placement, net of cash issuance costs	-	18,426
Net cash used in financing activities	<u>94</u>	<u>18,198</u>
Net change in cash and cash equivalents and restricted cash	(1,540)	18,186
Cash and cash equivalents and restricted cash at beginning of period	18,387	2,341
Cash and cash equivalents and restricted cash at end of period	<u>\$ 16,847</u>	<u>\$ 20,527</u>
<b>Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets</b>		
Cash and cash equivalents	\$ 16,495	\$ 20,312
Restricted cash	352	215
Total cash and restricted cash reported in the condensed consolidated balance sheets	<u>\$ 16,847</u>	<u>\$ 20,527</u>

**XTANT MEDICAL HOLDINGS, INC.**  
**CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA**  
(Unaudited, in thousands)

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Net Loss	\$ (1,710)	\$ (733)	\$ (3,923)	\$ (762)
Depreciation and amortization	317	357	599	731
Interest expense	397	199	757	201
Tax expense	13	43	35	64
Non-GAAP EBITDA	<u>(983)</u>	<u>(134)</u>	<u>(2,532)</u>	<u>234</u>
Non-GAAP EBITDA/Total revenue	-6.4%	-0.9%	-9.0%	0.9%
<b>NON-GAAP ADJUSTED EBITDA CALCULATION</b>				
Non-cash compensation	571	465	1,185	921
Separation-related expenses	-	-	3	-
Litigation reserve	-	550	-	550
Non-GAAP Adjusted EBITDA	<u>\$ (412)</u>	<u>\$ 881</u>	<u>\$ (1,344)</u>	<u>\$ 1,705</u>
Non-GAAP Adjusted EBITDA/Total revenue	-2.7%	5.9%	-4.8%	6.2%